ArticleJACC. Case reports2025
Resistant Hypertension Treated With Extravascular Renal Denervation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of extravascular renal denervation in patients with resistant hypertension: a study protocol for a pilot, single-arm, multi-center, first-in-human study.Clinical hypertension · 2026Article
- Renal denervation revisited: is patient selection the missing link between failure and success?Clinical hypertension · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistant hypertension is defined as uncontrolled blood pressure (BP) even with 3 or more antihypertensive drugs. Catheter-based intravascular renal denervation has shown only modest benefits, prompting the development of extravascular renal denervation (eRDN), the HyperQure RDN System. To the best of our knowledge, this is the first reported experience of eRDN performed in 2 patients with severe resistant hypertension. Notable BP reductions were observed in 24-hour ambulatory BP from 140/96 to 104/70 mm Hg (case 1) and from 199/117 to 104/61 mm Hg (case 2) after 3 months. Fewer oral BP medications were then prescribed thereafter. No postoperative complications were also observed. Thus, eRDN may safely and effectively treat patients with resistant hypertension. Additionally, eRDN may offer a promising alternative to intravascular renal denervation, especially in patients with renal arterial variations such as accessories or early branching arteries, for which the intravascular approach is unsuitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.